NCCN Adds Nirogacestat to Guidelines for Patients With Soft Tissue Sarcoma

The NCCN has updated their guidelines for soft tissue sarcoma to include the γ-secretase inhibitor nirogacestat as a systemic therapy option for patients with desmoid tumors, granting the agent a preferred, category 1 recommendation.

Related Keywords

United States ,Americans ,Richard Pazdur ,Office Of Oncologic Diseases ,National Comprehensive Cancer Network ,Oncology Center ,Oncologic Diseases ,Drug Evaluation ,Practice Guidelines ,Soft Tissue Sarcoma Guidelines ,Version 3 2023 ,Preferred ,Ategory 1 Recommendation ,Nirogacestat ,Ogsiveo ,Phase 3 Defi Trial Nct03785964 ,